LFB, a company committed to saving patients
LFB is a French biopharmaceutical group that develops, manufactures and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases.
Created in France in 1994, LFB today is a leading European company providing plasma-derived medicinal products to healthcare professionals. Its mission is to offer patients new treatment options for unmet needs in three major therapeutic areas: immunology, haemostasis, and intensive care.
LFB is a public company operating in a competitive sector. LFB currently markets about fifteen medicinal products in more than 30 countries.
Interview with Jacques Brom, CEO of LFB
Major objectives, commitments to patients and employees and industrial challenges: Jacques Brom looks back in video on a year of growth and the mission of LFB employees: their commitment to serve patients.
LFB at a glance
-
2,880 employees worldwide in 2023
-
-
